International Immunology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 10, 2025
Abstract
Since
the
first
approval
of
an
immune-checkpoint
inhibitor,
we
have
witnessed
clinical
success
cancer
immunotherapy.
Adoptive
T-cell
therapy
with
chimeric
antigen-receptor
T
(CAR-T)
cells
has
shown
remarkable
efficacy
in
hematological
malignancies.
Concurrently
these
successes,
immunoediting
concept
that
refined
immunosurveillance
underpinned
scientific
mechanism
and
reason
for
past
failures,
as
well
recent
breakthroughs
Now,
face
next
step
issues
to
be
solved
this
field,
such
tumor
heterogeneity,
microenvironment,
metabolism
tumors
immune
system,
personalized
approaches
patients,
aiming
expand
population
benefitted
by
therapies.
Cancer Discovery,
Journal Year:
2021,
Volume and Issue:
11(4), P. 933 - 959
Published: April 1, 2021
Abstract
Strategies
to
therapeutically
target
the
tumor
microenvironment
(TME)
have
emerged
as
a
promising
approach
for
cancer
treatment
in
recent
years
due
critical
roles
of
TME
regulating
progression
and
modulating
response
standard-of-care
therapies.
Here,
we
summarize
current
knowledge
regarding
most
advanced
TME-directed
therapies,
which
either
been
clinically
approved
or
are
currently
being
evaluated
trials,
including
immunotherapies,
antiangiogenic
drugs,
treatments
directed
against
cancer-associated
fibroblasts
extracellular
matrix.
We
also
discuss
some
challenges
associated
with
future
perspectives
this
evolving
field.
Significance:
This
review
provides
comprehensive
analysis
therapies
targeting
TME,
combining
discussion
underlying
basic
biology
clinical
evaluation
different
therapeutic
approaches,
highlighting
perspectives.
Journal of Hematology & Oncology,
Journal Year:
2021,
Volume and Issue:
14(1)
Published: June 9, 2021
Single-cell
sequencing,
including
genomics,
transcriptomics,
epigenomics,
proteomics
and
metabolomics
is
a
powerful
tool
to
decipher
the
cellular
molecular
landscape
at
single-cell
resolution,
unlike
bulk
which
provides
averaged
data.
The
use
of
sequencing
in
cancer
research
has
revolutionized
our
understanding
biological
characteristics
dynamics
within
lesions.
In
this
review,
we
summarize
emerging
technologies
recent
progress
obtained
by
information
related
landscapes
malignant
cells
immune
cells,
tumor
heterogeneity,
circulating
underlying
mechanisms
behaviors.
Overall,
prospects
facilitating
diagnosis,
targeted
therapy
prognostic
prediction
among
spectrum
tumors
are
bright.
near
future,
advances
will
undoubtedly
improve
highlight
potential
precise
therapeutic
targets
for
patients.
Nature Reviews Drug Discovery,
Journal Year:
2023,
Volume and Issue:
22(4), P. 295 - 316
Published: Feb. 9, 2023
Galectins
are
a
family
of
endogenous
glycan-binding
proteins
that
have
crucial
roles
in
broad
range
physiological
and
pathological
processes.
As
group,
these
use
both
extracellular
intracellular
mechanisms
as
well
glycan-dependent
independent
pathways
to
reprogramme
the
fate
function
numerous
cell
types.
Given
their
multifunctional
tissue
fibrosis
cancer,
galectins
been
identified
potential
therapeutic
targets
for
disorders.
Here,
we
focus
on
relevance
galectins,
particularly
galectin
1
(GAL1),
GAL3
GAL9
tumour
progression
fibrotic
diseases.
We
consider
an
array
galectin-targeted
strategies,
including
small-molecule
carbohydrate
inhibitors,
natural
polysaccharides
derivatives,
peptides,
peptidomimetics
biological
agents
(notably,
neutralizing
monoclonal
antibodies
truncated
galectins)
discuss
action,
selectivity
preclinical
models
cancer.
also
review
results
clinical
trials
aim
evaluate
efficacy
inhibitors
patients
with
idiopathic
pulmonary
fibrosis,
nonalcoholic
steatohepatitis
The
rapid
pace
glycobiology
research,
combined
acute
need
drugs
alleviate
inflammation
overcome
resistance
anticancer
therapies,
will
accelerate
translation
anti-galectin
therapeutics
into
practice.
Rabinovich
colleagues
cancer
various
strategies
target
progress
trials.
Cancer Communications,
Journal Year:
2023,
Volume and Issue:
43(5), P. 525 - 561
Published: April 2, 2023
Abstract
Tumor
development
and
metastasis
are
facilitated
by
the
complex
interactions
between
cancer
cells
their
microenvironment,
which
comprises
stromal
extracellular
matrix
(ECM)
components,
among
other
factors.
Stromal
can
adopt
new
phenotypes
to
promote
tumor
cell
invasion.
A
deep
understanding
of
signaling
pathways
involved
in
cell‐to‐cell
cell‐to‐ECM
is
needed
design
effective
intervention
strategies
that
might
interrupt
these
interactions.
In
this
review,
we
describe
microenvironment
(TME)
components
associated
therapeutics.
We
discuss
clinical
advances
prevalent
newly
discovered
TME,
immune
checkpoints
immunosuppressive
chemokines,
currently
used
inhibitors
targeting
pathways.
These
include
both
intrinsic
non‐autonomous
TME:
protein
kinase
C
(PKC)
signaling,
Notch,
transforming
growth
factor
(TGF‐β)
Endoplasmic
Reticulum
(ER)
stress
response,
lactate
Metabolic
reprogramming,
cyclic
GMP–AMP
synthase
(cGAS)–stimulator
interferon
genes
(STING)
Siglec
also
recent
Programmed
Cell
Death
Protein
1
(PD‐1),
Cytotoxic
T‐Lymphocyte
Associated
4
(CTLA4),
T‐cell
immunoglobulin
mucin‐3
(TIM‐3)
Lymphocyte
Activating
Gene
3
(LAG3)
checkpoint
along
with
C‐C
chemokine
receptor
(CCR4)‐
class
chemokines
22
(CCL22)/
17
(CCL17),
type
2
(CCR2)‐
(C‐C
motif)
ligand
(CCL2),
5
(CCR5)‐
(CCL3)
axis
TME.
addition,
review
provides
a
holistic
TME
as
three‐dimensional
microfluidic
models
believed
recapitulate
original
characteristics
patient
hence
may
be
platform
study
mechanisms
screen
for
various
anti‐cancer
therapies.
further
systemic
influences
gut
microbiota
reprogramming
treatment
response.
Overall,
comprehensive
analysis
diverse
most
critical
highlighting
newest
preclinical
studies
underlying
biology.
highlight
importance
technologies
microfluidics
lab‐on‐chip
research
present
an
overview
extrinsic
factors,
such
inhabitant
human
microbiome,
have
potential
modulate
biology
drug
responses.
Journal of Hematology & Oncology,
Journal Year:
2022,
Volume and Issue:
15(1)
Published: July 7, 2022
The
development
of
combination
immunotherapy
based
on
the
mediation
regulatory
mechanisms
tumor
immune
microenvironment
(TIME)
is
promising.
However,
a
deep
understanding
immunology
must
involve
systemic
environment
(STIE)
which
was
merely
illustrated
previously.
Here,
we
aim
to
review
recent
advances
in
single-cell
transcriptomics
and
spatial
for
studies
STIE,
TIME,
their
interactions,
may
reveal
heterogeneity
responses
as
well
dynamic
changes
essential
treatment
effect.
We
evidence
from
preclinical
clinical
related
significance
overall
survival,
through
different
immunomodulatory
pathways,
such
metabolic
neuro-immunological
pathways.
also
evaluate
interactions
after
local
radiotherapy
or
combined
immunotherapy.
focus
our
lung
cancer,
hepatocellular
carcinoma,
nasopharyngeal
aiming
reshape
STIE
TIME
enhance
efficacy.
